A few things from the Acutaas Annual Report for FY2025:
The word Acutaas is inspired by the Latin word acutus — meaning sharp, keen, or perceptive
The count of commercialized products is now 610+ (this was 570+ last year)
Company’s advanced capabilities across multiple synthesis stages ensure a steady pipeline; focused on new technology platforms such as Flow reactors, DCS, etc.
The company completed the majority of its capital expenditure at its Ankleshwar facility and secured a long-term supply agreement with a subsidiary of an innovator pharmaceutical company for four new pharmaceutical intermediates targeting a single API under the CDMO model. Ankleshwar facility is fully automated, incorporating a Distributed Control System (DCS) for centralized monitoring and control of operations, along with a Powder Transfer System (PTS) that enables enclosed, contact-free material handling. The plant features three dedicated production blocks equipped with over 80 reactors and approximately 35 dryers. It is GMP-certified under ICH Q7 guidelines for the manufacture and dispatch of pharmaceutical intermediates. The new plant is among the one of first automated facilities for advanced intermediates in India.
The Sachin unit houses 13 independent product lines, supported by 40 reactors and 17 dryers. Company’s Board has approved capex for a new pilot plant facility at Sachin. The pilot plant will help expedite scaling up of new products as well as manufacturing of High Potent chemicals and the new products under CRAMS model.
The Jhagadia plant is equipped with 31 stainless steel and 14 glass-lined reactors. The facility is spread across a sizable land parcel, of which 15,830 square meters was unutilized. We are now leveraging this space to establish a new plant for Battery Chemicals. Civil works for electrolyte additives plant is in process, and commissioning is on track for the second half of FY2026
Under the Advanced Pharma Intermediates vertical, the company offers capabilities to manufacture up to N–1 stages of intermediates across multiple routes of synthesis (ROS). A significant differentiator lies in our backward integration strategy — over 90 % of our pharmaceutical intermediates are integrated with basic chemicals.
In Specialty Chemicals, Acutaas is the only manufacturer of semiconductor-grade photoresist chemicals in India. In Battery Chemicals, a healthy innovation pipeline with ~10 products under development, targeted toward next-generation lithium-ion and alternative battery technologies. Key products in this segment include Vinylene Carbonate and Fluoroethylene Carbonate, among others. We have firm orders on hand for the electrolytes business.
Our goal of achieving Rs.1,000 Crore in CDMO revenue by FY2028 is well within sight
We have significantly reduced our dependence on Chinese imports, bringing China’s share of raw material imports down from more than 70 % to 21 % by 2025.
Our operations are supported by a robust Distributed Control System (DCS)* that ensures precision and consistency across batch processes and utilities. We have also adopted Powder Transfer Systems to improve material handling and containment, particularly for high-potency APIs. With advanced fully automated drying technologies, our processes are faster, cleaner, and more reliable.
We are working on Photochemistry to unlock cleaner reaction pathways and novel compound synthesis. This is currently in R&D stage (Comment: Again, we see the continuous quest to move up the value chain and adopt newer, niche, emerging, high value-added technologies by the company).
Working on vertical gravity flow systems for safer, more energy-efficient batch processing.
Did over 100 customer and regulatory inspections in FY2025.
During the year, the company received process patents for its one invention in the pharma intermediates business. Company now boasts a robust portfolio of 10 process patents. We have filed applications for seven more process patents (in respect of intermediates used in the manufacture of generic API across therapeutic segments).
Board has approved to inject Rs.200 crores for establishment of manufacturing facility in South Korea through a joint venture company. (It is interesting to see that though the Baba Fine Chem acquisition was made to get a foot into the semiconductor space, the South Korea foray is happening through a 100 % subsidiary, sidestepping BFC altogether. This will ensure benefits of the semiconductor foray are not diluted for the Acutaas shareholders, since company’s stake in BFC only 55 %). Smart strategy by the company.
Very good set of numbers. At this point of time company’s major portion of revenue comes from pharma. But, I am more interested in Specialty Chemicals segment which contributes 14% approx to the revenue.
Acutaas claims they are the only biggest manufacturer of electrolyte additives outside china. Therefore are positioned to take advantage of Battery Energy Storage System (BESS) opportunity that are coming in Energy sector.
Plus they also make semiconductor grade photoresist chemicals in India. As there are huge multiple semiconductor plants made in Dholera, Gujarat by reputed player like Tata, ReNew, Kaynes etc. Plus Torrent power has already made a huge power plant to serve electricity. This also present future opportunity to Acutaas.
What the article above is missing is their semiconductor and EV chemical business, which is kicking off next year. They already have a client locked in, and trials are going to start by the end of this year, if I remember correctly. If all three businesses scale well, the premiums it’s getting are justified. I agree with the risks associated with it. We need to monitor their execution closely. Note: I’ve been tracking this company for the last three years. Invested and biased.
Here is a summary of the key pros and cons for Acutas Chemicals based on their Q4 FY26 earnings call:
Pros (Strengths and Growth Drivers)
Record Financial Performance: The company reported its highest ever Profit After Tax (PAT) of Rs 356.4 crore for FY26, which more than doubled year-over-year. FY26 revenue reached Rs 1,339.4 crore, representing a 33% year-over-year increase.
Strong Margins: Overall EBITDA margins expanded significantly to 42.4% in Q4, driven by an improved product mix. Specifically, the pharmaceutical business delivered a 44% EBITDA margin, while the specialty chemical segment improved to 29%. Management expects to maintain these margin levels into FY27.
High Revenue Visibility: Management confidently provided a 25% revenue growth guidance for FY27.
Robust CDMO Pipeline: The company’s 10-year supply agreement with Fermion provides long-term stability, and they have just validated four new CDMO products. Each of these new products has a peak revenue potential of Rs 50 to 100 crore.
Sold-Out Battery Chemical Capacity: The company’s 2,000 metric ton capacity for electrolyte additives (VC and FEC) is completely backed by signed, long-term customer contracts for the next three years.
Accelerated Semiconductor Expansion: The construction of the South Korean joint venture (Indicam) is running ahead of schedule and is expected to be completed in the second half of calendar year 2026. Its R&D center is already fully operational and actively sending samples to prospective customers to accelerate commercialization.
Future R&D Investments: Acutas is planning an ambitious 10x capacity expansion of its R&D center to create a versatile, multi-disciplinary facility that caters to pharmaceuticals, battery chemicals, semiconductors, and cosmetics under one roof.
Portfolio Upgrades: The company successfully reshuffled its pharmaceutical intermediate portfolio to drive margin expansion and is beginning a systematic phase-out of lower-margin commodity chemicals to replace them with higher-value differentiated offerings.
Cons (Risks and Challenges)
Supply Chain and Cost Pressures: The ongoing conflict in the Gulf region has disrupted supply chains for key feedstocks, reduced vessel availability, and pushed raw material prices and deep-sea freight costs higher.
Working Capital Increase: The company’s working capital cycle increased from 114 days to 120 days in FY26, which was offset by lower payable days despite improvements in debtor and inventory days.
Project Delays: The new pilot plant at the Sachin site has been slightly delayed until Q2 FY27 due to late equipment arrivals.
Inherent Seasonality: The company experiences strong seasonal fluctuations, with Q1 historically being their weakest quarter. This pattern typically results in the first half of the year contributing only 40% of the top line, while the second half accounts for 60%.
Recent Segment Volatility: The existing semiconductor business under Baba Fine Chemicals went through a “difficult phase” in the last financial year, though management notes it has been recovering since Q4.
Unit 2 utilization %: The single biggest driver for margin expansion (Target: >50% by FY27) came at 31% vs 38% last qtr
Not much is known about Acutaas’ semiconductor JV in South Korea, and I have felt the management has been a little secretive about it, not sure why. When the JV was formed, the company identified a “J & Materials Co. Ltd” as the JV partner but last week Mr. Abhishek Patel said the partner is a “proprietary firm” and the unnamed partner has more than 30 years of experience in the field.
A recent interview of Mr. Nareshbhai Patel in the Korean media identifies one Mr. Han Jae-seong as the partner with whom Acutaas has tied up. Apparently, Mr. Han Jae-seong identifies himself as Mr. Jay Han in English who started his career as a photolithography researcher with Samsung Electronics more than 30 years ago. He says the Indichem partnership “…aims to integrate India — relatively low in geopolitical risk — into Korea’s semiconductor materials supply chain, enabling stable sourcing of advanced semiconductor chemicals while supporting import substitution for materials traditionally supplied by Japan and China.” His Linked-In profile also gives the photographs of the Indichem factory under construction, such as this:
